Becky L Genberg1, William H Rogers2, Yoojin Lee1, Danya M Qato1,3, David D Dore1,4,5, David S Hutchins6, Troyen Brennan6, Olga S Matlin6, Ira B Wilson1. 1. Department of Health Services, Policy, and Practice; School of Public Health, Brown University, Providence, RI, USA. 2. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. 3. University of Maryland School of Pharmacy, Department of Pharmaceutical Health Services Research, Baltimore, Maryland USA. 4. Department of Epidemiology, School of Public Health, Brown University, Providence, RI, USA. 5. Optum Epidemiology, Waltham, MA, USA. 6. CVS Caremark, Woonsocket, RI, USA.
Abstract
PURPOSE: The objective of this study was to determine the fraction of variance in patient-level medication adherence accounted for by prescribers and pharmacies. METHODS: We used prescription drug claims paid between January 2010 and July 2011 to a national pharmacy benefits manager to define implementation during persistent episodes. Patients in Massachusetts or Rhode Island covered by Blue Cross Blue Shield of Rhode Island and their prescribers were included. Five drug classes were analyzed: angiotensin converting enzyme (ACE) inhibitors, antihyperglycemics (ANHGs), drugs for prostatic hyperplasia (PH), statins, and levothyroxine (THYR). We performed mixed models with random intercepts (drug, patient, prescriber, and pharmacy) and examined the fraction of variance explained at each level using intraclass correlations. RESULTS: Overall implementation ranged from 87 to 91%. The fraction of the explained variance in implementation to ACEs, ANHG, PH, statins, and THYR accounted for by prescribers was 16.4%, 12.6%, 14.6%, 15.6%, and 15% respectively; and for pharmacies 20.4%, 20%, 15.2%, 10.6%, and 9.4%, respectively. CONCLUSIONS: Prescriber and pharmacy effects accounted for a substantial amount of the explained variance in implementation across all five drug classes. Adherence interventions for chronic conditions that target prescribers and pharmacies, in addition to patients, could be effective and efficient.
PURPOSE: The objective of this study was to determine the fraction of variance in patient-level medication adherence accounted for by prescribers and pharmacies. METHODS: We used prescription drug claims paid between January 2010 and July 2011 to a national pharmacy benefits manager to define implementation during persistent episodes. Patients in Massachusetts or Rhode Island covered by Blue Cross Blue Shield of Rhode Island and their prescribers were included. Five drug classes were analyzed: angiotensin converting enzyme (ACE) inhibitors, antihyperglycemics (ANHGs), drugs for prostatic hyperplasia (PH), statins, and levothyroxine (THYR). We performed mixed models with random intercepts (drug, patient, prescriber, and pharmacy) and examined the fraction of variance explained at each level using intraclass correlations. RESULTS: Overall implementation ranged from 87 to 91%. The fraction of the explained variance in implementation to ACEs, ANHG, PH, statins, and THYR accounted for by prescribers was 16.4%, 12.6%, 14.6%, 15.6%, and 15% respectively; and for pharmacies 20.4%, 20%, 15.2%, 10.6%, and 9.4%, respectively. CONCLUSIONS: Prescriber and pharmacy effects accounted for a substantial amount of the explained variance in implementation across all five drug classes. Adherence interventions for chronic conditions that target prescribers and pharmacies, in addition to patients, could be effective and efficient.
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: David J Meyers; Megan B Cole; Momotazur Rahman; Yoojin Lee; William Rogers; Roee Gutman; Ira B Wilson Journal: AIDS Date: 2019-07-22 Impact factor: 4.177
Authors: David J Meyers; Megan B Cole; Momotazur Rahman; Yoojin Lee; William Rogers; Roee Gutman; Ira B Wilson Journal: AIDS Date: 2019-11-01 Impact factor: 4.177
Authors: Andrew R Zullo; Tingting Zhang; Geetanjoli Banerjee; Yoojin Lee; Kevin W McConeghy; Douglas P Kiel; Lori A Daiello; Vincent Mor; Sarah D Berry Journal: J Am Geriatr Soc Date: 2018-01-16 Impact factor: 5.562
Authors: H J Appaneal; A R Caffrey; V V Lopes; V Mor; D M Dosa; K L LaPlante; T I Shireman Journal: J Hosp Infect Date: 2021-02-05 Impact factor: 3.926